Buy Archives - Healthy News

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

The Medical Instruments industry has witnessed a significant transformation in the nature of business lately, leading to increased investment in R&D for the development of cutting-edge technologies. The dynamic nature of the healthcare crisis over the past two and a half years has further altered the industry landscape, putting robotic and remote medical services in the limelight. Despite the reopening of the economy, deteriorating international trade, with global inflationary pressure leading to an extremely tough situation related to raw material and labor cost as well as freight charges, has put the industry in a tight spot again. Further, industry watchers are still unable to gauge the magnitude of economic revival due to the emergence of new COVID strains in selective parts of the world from time to time.

The just-reported fourth-quarter result of a number of medical instrument companies confirmed a gradual rebound in their base businesses through the latter half of 2022. However, the industry-wide trend of staffing shortages and supply chain-related hazards are denting growth. Meanwhile, industry players like Edwards Lifesciences EW, IDEXX Laboratories IDXX and Hologic, Inc. HOLX have adapted well to changing consumer preferences and are still witnessing an uptrend in their stock prices.

Industry Description

The Zacks Medical – Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. This FDA-regulated industry comprises an endless number of products, starting from transcatheter valves to orthopedic products to imaging equipment and robotics. Prior to the pandemic, the Medical Instruments space was advancing well in terms of R&D. Among the recent path-breaking inventions, bone growth stimulators, 3D mapping of CT scans, wireless brain sensors and human-brain pacemakers are worth mentioning. During the COVID-hit years, many non-COVID and non-emergency-line innovations were stuck or delayed. However, with the severity of the pandemic easing, the industry players are again more focused on strengthening their pipeline.

3 Trends Shaping the Future of the Medical Instruments Industry

Business Trend Disruption: Considering the ongoing macro-economic situation, the IMF came up with its January 2023 World Economic Outlook Update. The update noted that global growth might slightly slow down from 3.4{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} in 2022, to 2.9{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} in 2023, then again rebound to 3.1{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} in 2024. IMF specifically addressed the ongoing tightening financial conditions in most regions, staffing shortages, Russia’s continued aggression, all of which have been weighing heavily on the medical instrument outlook despite the decline in COVID-19 severity. Per IMF, through 2023, inflation could remain stubbornly high, with continued labor market tightness and growing wage pressures requiring tighter monetary policies. On a brighter note, strengthening household balance sheets and wage growth are driving private demand. Overall, the Medical Instruments industry players are expected to collectively report a year-over-year decline in their revenues due to logistical challenges and increasing unit cost. This might get offset by an increase in essential and non-essential product demand by private households.

M&A Trend Continues: The medical instruments space has been benefiting from the ongoing merger and acquisition (M&A) trend. In fact, various reports suggest that M&A has been the key catalyst in the U.S. MedTech space of late. It is a known fact that smaller and mid-sized industry players attempt to compete with the big shots through consolidation. The big players attempt to enter new markets through a niche product. Among the significant deals of recent times, in December 2022, Johnson & Johnson completed the $16.6-billion mammoth acquisition of Abiomed. In February 2023, Abbott announced its plans to acquire Cardiovascular Systems, a medical device company with advanced atherectomy system used in treating peripheral and coronary artery disease. The same month, Globus Medical announced its plans to acquire the San-Diego based spine technology firm, NuVasive Inc., in an all-stock deal valued at around $3.1 billion.

Meanwhile, a MedTech Dive report of January 2023 revealed that MedTech players are expected to demonstrate a slow start to 2023 in terms on M&A. Yet, the experts say that despite higher interest rates and a volatile stock market, there are signs that strategic M&As are poised to rebound.

Digital Revolution: With an increase in the adoption of digital platforms within the medical device space, robotic surgeries, big-data analytics, bioprinting, 3D printing, electronic health records (EHR), predictive analytics, real-time alerting and revenue cycle management services are gaining prominence in the United States. A June 2019 Health care News report suggested that this market, valued at $123 billion in 2018, has been witnessing a CAGR of 25{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f}. Various other reports suggest that companies that adopted AI witnessed a 50{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} reduction in treatment costs. Telemedicine stocks received an impressive response when, in 2021, the Centers for Disease Control and Prevention asked healthcare service communities to broaden the use of telemedicine.

Zacks Industry Rank Indicates Good Prospects

The Zacks Medical Instruments industry’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates encouraging near-term prospects. The industry, housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #85, which places it in the top 34{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of more than 250 Zacks industries. Our research shows that the top 50{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of the Zacks-ranked industries outperforms the bottom 50{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} by a factor of more than 2 to 1.

We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. But it’s worth taking a look at the industry’s shareholder returns and current valuation first.

Industry Underperforms S&P 500, Sector

The industry has underperformed the Zacks S&P 500 composite and its sector in the past year.

The industry has declined 9.5{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} compared with the S&P 500’s 6.9{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} fall in a year’s time. The broader sector has declined 9.3{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} in the said time frame.

One Year Price Performance

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

Industry’s Current Valuation

On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 33.06X compared with the broader industry’s 22.40X and the S&P 500’s 18.01X.

Over the past five years, the industry has traded as high as 45.08X, as low as 26.13X and at the median of 32.87X, as the charts show below.

Price-to-Earnings Forward Twelve Months (F12M)

Price-to-Earnings Forward Twelve Months (F12M)

3 Stocks to Buy Right Now

Hologic: Headquartered in Bedford, MA, Hologic develops, manufactures, and supplies diagnostics, medical imaging systems and surgical products, which cater to the healthcare needs of women. Hologic has been making impressive progress in its Breast Health arm in recent times. The company is currently focusing on expanding its strategy to diversify business across the patient continuum of care. The company’s GYN Surgical business too has transformed to the most profitable division of Hologic on a percentage basis banking on new leadership, strong strategic execution of new commercial models and new product launches.
The consensus estimate for this Zacks Rank #1 (Strong Buy) company’s 2024 sales is pegged at $4.12 billion, indicating a 3.7{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} rise year over year.

The consensus mark for Hologic’s 2024 EPS is pegged at $3.99, indicating an increase of 7.6{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} from the year-ago period.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Price and Consensus: HOLX

Edwards Lifesciences: Headquartered in Irvine, CA, Edwards Lifesciences deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. Edwards Lifesciences expects to maintain its leadership position in the global Transcatheter Aortic Valve Replacement market through an increased focus on expanding patient access by actively leveraging current valve platforms for additional indications. This includes developing next-generation valve platforms, and maintaining trusted relationships with clinicians, payers and regulators. Edwards Lifesciences also remain committed to aggressively investing in structural heart disease and critical care technologies.

The Zacks Consensus Estimate for Edwards Lifesciences’ 2023 sales is pegged at $5.86 billion, indicating an 8.8{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} rise year over year. The same for Edwards Lifesciences’ adjusted earnings is pegged at $2.52 per share, an expected growth of 1.6{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} from 2022. Edwards Lifesciences carries a Zacks Rank #2 (Buy).

Price and Consensus: EW

IDEXX: Headquartered in Delaware, NJ, IDEXX is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company is deriving strong top-line growth driven by continued benefits from the expansion of IDEXX’s global premium instrument installed base. CAG Diagnostics’ organic recurring revenue growth reflects solid gains across IDEXX’s major modalities globally, supported by growth in clinical service demand and expanded utilization of diagnostic products and services.

The consensus estimate for this Zacks Rank #2 company’s 2023 sales is pegged at $3.64 billion, indicating an 8{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} rise year over year. The same for IDEXX’s 2023 earnings is pegged at $9.51, an expected 18.4{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} growth from the year-ago period.

Price and Consensus: IDXX

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report

Hologic, Inc. (HOLX) : Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

A researcher tried to buy mental health data. It was surprisingly easy.

Delicate psychological health and fitness information is for sale by small-recognized data brokers, at moments for a several hundred dollars and with tiny hard work to conceal personal facts such as names and addresses, in accordance to study released Monday.

The research, conducted over two months at Duke University’s Sanford School of Community Plan, which scientific studies the ecosystem of businesses buying and promoting personalized information, consisted of asking 37 facts brokers for bulk knowledge on people’s psychological health. Eleven of them agreed to market data that identified individuals by issues, which includes melancholy, nervousness and bipolar problem, and generally sorted them by demographic data these types of as age, race, credit history rating and location.

The scientists did not buy the facts, but in lots of scenarios obtained cost-free samples to confirm that the broker was reputable, a typical business follow. The study doesn’t title the knowledge brokers.

Some of the brokers have been specifically cavalier with delicate knowledge. 1 produced no demands on how information it bought was used and marketed that it could supply names and addresses of people today with “depression, bipolar ailment, anxiety problems, worry condition, most cancers, put up-traumatic anxiety condition, obsessive-compulsive ailment and character problem, as well as people today who have had strokes and information on theirs races and ethnicities,” the report observed.

“[T]he industry seems to absence a established of best techniques for dealing with individuals’ mental wellbeing facts, notably in the areas of privateness and customer vetting,” the report identified.

While rates for rented and bought psychological health data diverse widely, some firms available them for low-priced, as very low as $275 for information on 5,000 men and women.

A researcher tried to buy mental health data. It was surprisingly easy.

Use of apps that offer you counseling and other psychological health and fitness expert services was already on the rise in advance of the Covid pandemic broke out. In April 2020, the Food and Drug Administration eased its tips towards unvetted psychological wellbeing apps, given the mixture of people’s strain from the pandemic and a push for distant health and fitness care.

Info brokers, which offer in the purchasing, repackaging and providing of people’s figuring out data and specifics about them, has grown into a flourishing but shadowy market. Companies in the business are not often household names and generally say small publicly about their business practices.

Congress has failed so significantly to pass important laws on the sector, which spends thousands and thousands on lobbying.

Not like some countries, the U.S. has no overarching privacy law that shields most people’s personal and private information and facts from becoming purchased and sold. Some professional medical facts can be safeguarded with rules like the Wellness Insurance Portability and Accountability Act, typically known as HIPAA. But HIPAA applies only when that information and facts is held by a unique “covered entity,” these types of as a hospital or particular sort of wellbeing care business.

Justin Sherman, a senior fellow at Duke’s Sanford Faculty of Public Coverage who runs its facts brokerage job and oversaw the report, stated other entities that retailer health and fitness information, which include most phone applications, are not regulated via HIPAA, leaving details brokers with a number of alternatives to legally purchase these knowledge.

“People presume HIPAA covers all sorts of wellness information all over the place. And that is not legitimate,” he reported.

“There are numerous, several locations in which this details could have appear from, since so several entities are not protected by HIPAA’s wellbeing info sharing constraints,” Sherman said.

Whilst the report does not delve into how the brokers obtained that mental overall health details in the initial location, a Buyer Stories investigation in 2021 located that some well-known mental health and fitness apps ended up sharing users’ knowledge with promotion businesses, together with Facebook.

A spokesperson for Meta, Facebook’s parent company, said in an email: “Advertisers should really not mail delicate information about individuals by way of our Business enterprise Instruments. Undertaking so is from our insurance policies and we educate advertisers on adequately placing up Organization instruments to stop this from occurring. Our system is developed to filter out possibly delicate info it is equipped to detect.”

Pam Dixon, the govt director of Globe Privacy Discussion board, a nonprofit group that works to make improvements to privateness protections nationally and globally, claimed that perplexing regulations all-around health care privacy make it almost unachievable for a human being to navigate the health and fitness info that can be envisioned to continue to be non-public.

“There is mass shopper confusion about when our wellness information are secured by health privacy law or not,” she claimed. “It’d be virtually extremely hard for the normal individual who’s not a privateness attorney to know if a website’s safeguarded by HIPAA or not.”

Dixon cautioned against concluding that facts about mental overall health was more extensively traded than other personalized information and facts and said the details brokerage business is out of management.

“There’s no attainable way at this issue in time that a human remaining, if they wished to, could opt out of all the information broker exercise in the world,” she stated.

“Remember, another person is obtaining this information, or there would not be a organization model for it,” she reported.

Penumbra: Today’s Best Medical Equipment Nearby Cap-Gain Buy (PEN)

The primary focus of this article is on the stock of Penumbra, Inc. (NYSE:PEN)

Investment Portfolio Discipline Summary

“Blockdesk’s Standard Performance Comparison fund invests in equities whenever Market-Maker hedging activity forecasts that 80{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} or more of the near-coming price range is expected to be to the upside and 10{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} or less may be to the downside. This is a guide to the balance of expectations, since coming price change directions tend to be led by prior extremes, issue by issue.

At the time of each purchase a GTC sell order at top of forecast price range for all of those just acquired shares can be placed with the broker where bought. His system will monitor and direct to you the confirmation of their sale when accomplished, probably with encouragement for reinvestment.

At the time of the buy, you should make a note to review this holding 3 months after the purchase with a mark on your own personal private calendar. If it is not yet sold, but at a loss, sell and put the proceeds into the reinvestment stream. If its gain has reached less than the target, after considering alternatives, you may decide to move the calendar note a month further forward – but just once. Or decide to take the then existing profit for reinvestment in a fresh price and time opportunity period.

Description of Primary Investment Candidate

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.”

Source: Yahoo Finance

street analyst estimates — Yahoo Finance

These growth estimates have been made by and are collected from Wall Street analysts to suggest what conventional methodology currently produces. The typical variations across forecast horizons of different time periods illustrate the difficulty of making value comparisons when the forecast horizon is not clearly defined.

Risk and Reward Balances Among PEN Competitors

Here are several healthcare equipment industry services like PEN. Following the same analysis as with PEN, historic sampling of their prior Risk-Reward balances like those of today were taken, and are mapped out in Figure 1.

Figure 1

(used with permission)

Expected rewards for these securities are the average gains from current closing market price seen worth protecting short positions. Their measure is on the horizontal green scale.

The risk dimension is of actual price draw-downs at their most extreme point while being held in previous pursuit of upside rewards similar to the ones currently being seen. They are measured on the red vertical scale.

Both scales are of percent change from zero to 25{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f}. Any stock or ETF whose present risk exposure exceeds its reward prospect will be above the dotted diagonal line. Capital-gain attractive to-buy issues are in the directions down and to the right.

Our principal interest is in PEN at location [7], near the right edge of the symbols cluster. A “market index” norm of reward~risk tradeoffs is offered by SPDR S&P 500 Index ETF SPY at [2]. Most appealing (to own) by this Figure 1 view is INSP.

Comparing features of Alternative Investment Stocks

The Figure 1 map provides a good visual comparison of the two most important aspects of every equity investment in the short term. There are other aspects of comparison which this map sometimes does not communicate well, particularly when general market perspectives like those of SPY are involved. Where questions of “how likely’ are present other comparative tables, like Figure 2, may be useful..

Yellow highlighting of the table’s cells emphasize factors important to securities valuations and the security PEN, best promising odds of near capital gain as ranked in column [R].

Figure 2

(used with permission)

Why do all this math?

Figure 2’s purpose is to attempt universally comparable answers, stock by stock, of a) How BIG the prospective price gain payoff may be, b) how LIKELY the payoff will be a profitable experience, c) how SOON it may happen, and d) what price draw-down RISK may be encountered during its holding period.

Readers familiar with our analysis methods after quick examination of Figure 2 may wish to skip to the next section viewing Price range forecast trends for PEN

Column headers for Figure 2 define investment-choice preference elements for each row stock whose symbol appears at the left in column [A]. The elements are derived or calculated separately for each stock, based on the specifics of its situation and current-day MM price-range forecasts. Data in red numerals are negative, usually undesirable to “long” holding positions.

Table cells with yellow fills are of data for the stocks of principal interest and of all issues at the ranking column, [R].

The price-range forecast limits of columns [B] and [C] get defined by MM hedging actions to protect firm capital required to be put at risk of price changes from volume trade orders placed by big-$ “institutional” clients.

[E] measures potential upside risks for MM short positions created to fill such orders, and reward potentials for the buy-side positions so created. Prior forecasts like the present provide a history of relevant price draw-down risks for buyers. The most severe ones actually encountered are in [F], during holding periods in effort to reach [E] gains. Those are where buyers are emotionally most likely to accept losses.

The Range Index [G] tells where today’s price lies relative to the MM community’s forecast of upper and lower limits of coming prices. Its numeric is the percentage proportion to the downside of the full low to high forecast seen below the current market price.

The use of prior market actions subsequent to RIs like today make it necessary that those priors be representative of experiences in the just-past 5 year period of 1261 market days. Any RI sample of less than 20 market days could have occurred in one month of 21 market days. Out of the 5 years of 60 months such performance might well be not representative of the whole period.

[H] tells what proportion of the [L] sample of prior like-balance forecasts have earned gains by either having price reach its [B] target or be above its [D] entry cost at the end of a 3-month max-patience holding period limit. [ I ] gives the net gains-losses of those [L] experiences.

What makes PEN most attractive in the group at this point in time is its basic strength of reward to risk ratio of 1.9 to 1 in [T].

Further Reward~Risk tradeoffs involve using the [H] odds for gains with the 100 – H loss odds as weights for N-conditioned [E] and for [F], for a combined-return score [Q]. The typical position holding period [J] on [Q] provides a figure of merit [fom] ranking measure [R] useful in portfolio position preferencing. Figure 2 is row-ranked on [R] among alternative candidate securities, with ISPN in top rank.

Along with the candidate-specific stocks these selection considerations are provided for the averages of some 3000+ stocks for which MM price-range forecasts are available today, and 20 of the best-ranked (by fom) of those forecasts, as well as the forecast for S&P500 Index ETF (SPY) as an equity-market proxy.

Current-market index SPY is not competitive as an investment alternative with its Range Index of 39 indicating the other 2/3rds of its forecast range is to the upside, yet little more than 7/10ths of previous SPY forecasts at this range index produced profitable outcomes, with enough losers to put its average in single-(whole) digit positive result in column [ I ].

As shown in column [N] of figure 2, those levels in comparison to their row forecasts [E] vary significantly between stocks. What matters is the net profit between investment gains and losses actually achieved following the forecasts, shown in column [I]. The Win Odds of [H] tells what proportion of the Sample RIs of each stock were profitable. Odds below 80{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} often have proven to lack reliability.

Price range forecast trends for PEN

Figure 3

daily forecast update trends — blockdesk.com

(used with permission)

No, this is not a “technical analysis chart” showing only historical data. It is a Behavioral Analysis picture of the Market-Making community’s actions in hedging investments of the subject. Those actions define expected price change limits shown as vertical bars with a heavy dot at the closing price on the date of the forecast.

It is an actual picture of experienced market professionals expected future prices, not a simple hope of a recurrence of the past. These expectations are backed up by significant bets of investment capital made to protect market-makers or to earn a proprietary profit from risk-taking.

The special value of such pictures is their ability to immediately communicate the balance of expectation attitudes between optimism and pessimism. We quantify that balance by calculating what proportion of the price-range uncertainty lies to the downside, between the current market price and the lower expected limit, labeled the Range Index [RI].

Prior periods like the current, where price is at or even below the bottom of the forecast range, have typically been followed by higher market prices and forecast price ranges.

In this structure a RI at zero indicates no further price decline is likely, but not guaranteed. The odds of 3 months passing without either reaching or exceeding the upper forecast limit or being at that time below the expected lower price (today’s) are quite slight.

The probability function of price changes for PEN are pictured by the (thumbnail) lower Figure 3 frequency distribution of the past 5 years of RI values with the today value indicated. Virtually all prior prices and coming price range forecasts have been at a higher level.

Conclusion

The multi-path valuations explored by the analysis covered in Figure 2 is rich testimony to the near-future value prospect advantage of a current investment in Penumbra Inc. over and above the other compared alternative investment candidates.